Find More Contacts for ENTEROME
Protected Content
Admin, Admin, Finance
Director
1 email found
View contacts for ENTEROME to access new leads and connect with decision-makers.
View All Contacts
  • Company Type For Profit
  • Contact Email media@enterome.com
  • Phone Number 33 1 76 21 58 19

Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or

actions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.

Lists Featuring This Company

Paris Companies With Fewer Than 1000 Employees (Top 10K)
9,990 Number of Organizations • $54.9B Total Funding Amount • 10,963 Number of Investors
France Companies With More Than 50 Employees (Top 10K)
9,405 Number of Organizations • $150B Total Funding Amount • 6,517 Number of Investors
Ile-de-France Companies With Fewer Than 1000 Employees (Top 10K)
9,301 Number of Organizations • $64.9B Total Funding Amount • 12,747 Number of Investors
Paris Companies With More Than 10 Employees (Top 10K)
9,676 Number of Organizations • $80.7B Total Funding Amount • 8,614 Number of Investors

Frequently Asked Questions

Where is ENTEROME's headquarters? ENTEROME is located in Paris, Ile-de-France, France.Who invested in ENTEROME? ENTEROME has 12 investors including The Leukemia & Lymphoma Society’s Therapy Acceleration Program and Seventure Partners.How much funding has ENTEROME raised to date? ENTEROME has raised .When was the last funding round for ENTEROME? ENTEROME closed its last funding round on Oct 30, 2023 from a Venture - Series Unknown round.Who are ENTEROME's competitors? Alternatives and possible competitors to ENTEROME may include Interius BioTherapeuticsTmunity Therapeutics, and Affimed.